Mr. Zhang was appointed as an independent non-executive director on June 2020. Mr. Zhang, as a Chinese Certified Public Accountant and Senior Accountant, graduated in accounting from Jiangxi University of Finance and Economics, the PRC in July 1985, and graduated in law from Party School of the Central Committee of C.P.C in December 2001. Mr. Zhang previously worked at the Industry and Transport Division of the Department of Finance of Jiangsu Province, Jiangsu High and New Technology Venture Capital Company, Jiangsu Assets and Equity Exchang and Jiangsu Asset Appraisal Company. Also he served as the director of Jiangsu Certified Public Accountants Company, was the director of the asset appraisal center under the Department of Finance of Jiangsu Province and held the division chief of Jiangsu Rural Comprehensive Reform Working Group Office.

Mr. Tang has served as a non-executive director of the company since May 2015. Mr. Tang obtained his bachelor’s double degree in mechanical engineering and business management from Huaqiao University. Mr. Tang's main experience includes: from 1991 to 1993, he served as a department manager of Shenzhen Shekou Foreign Economic Development Company; from 1993 to 1996, he served as the general manager of Shenzhen Yuesi Industrial Co., Ltd; since 1996, he has been the chairman of the board of directors at Shenzhen Finevalue Technology Co., Ltd.; since April 2013, he has served as the director of Shenzhen Qianhai Yuanben Equity Investment Fund Management Co., Ltd.; since July 2013, he has been appointed representative of the executive affairs partner of Suzhou Ruiyuan Shengben Biomedical Management Partnership (Limited Partnership); since July 2017, he has been the chairman of the board of directors of Jiangsu Xinyun Capital Management Co., Ltd.

Dr. Shen was appointed as an independent non-executive director on June, 2024. Dr. Shen obtained his bachelor’s degree in pharmacy from Shanghai First Medical College in August 1975, obtained his master of science in pharmacy from Shanghai Medical University in July 1986, obtained his doctoral degree in pharmacy from Kyoto University in Japan in September 1993, and engaged in postdoctoral research in pharmacy at Shanghai Institute of Materia Medica, Chinese Academy of Sciences from January 1994 to September 1995. From September 1995 to May 2016, he worked as a researcher and PhD supervisor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has served as the chairman of the board of directors of Shanghai Ringene Biopharma Co. Ltd. since September 2018 and an independent director of Yantai MabPlex International Biomedical Co., Ltd. since January 2022.

Dr. Feng was appointed as an independent non-executive director from November 2021. Dr. Feng obtained his bachelor’s degree in medicine from Shanghai First Medical College (now known as Shanghai Medical College of Fudan University) in December 1982 and a doctor’s degree in diagnostic radiology in December 1988. He served as the deputy dean and secretary of the Party Committee at Huashan Hospital of Fudan University from April 2000 to May 2008. From May 2007 to June 2011, he served as the dean of Shanghai Medical College of Fudan University. He served as the vice president of Fudan University from May 2011 to July 2015 and since August 2016, he served as a tenured professor at Huashan Hospital of Fudan University. He has been appointed as the chairman of Lunqin (Shanghai) Medical Technology Co., Ltd since November 2016. He served as the dean of Shanghai Penta Innovation & Entrepreneurship Institute since January 2018. He also served as the president of Shanghai Society of Biotechnology since October 2018.

Mr. Xiong is the chairman of the board, executive director and the legal representative of our company. He is responsible for the overall management, implementing decisions and operations of the Company. Mr. Xiong obtained his bacherlor's degree in investment economics management from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) and MBA from the Chinese University of Hong Kong. Mr.Xiong has more than 20 years of experience in pharmaceutical investment and management of pharmaceutical enterprises. Mr. Xiong had perviously worked at Guolian Fund Management Co., Ltd., Shanghai Union Biopharm.Co., Ltd., and etc. Now Mr.Xiong acts as the chairman of the Company, and executive director, chairman and general manager of several subsidiaries of the Company, and executive director of Shanghai Baoying Asset Management Co., Ltd.

Dr. Yang was appointed as an independent non-executive director on June, 2024. Dr. Yang obtained her bachelor’s degree in pharmaceutical business management from Shenyang Pharmaceutical University in July 1995, obtained her master’s degree in pharmacology from Shenyang Pharmaceutical University in July 1998, and obtained her doctoral degree in pharmacy from Shenyang Pharmaceutical University in July 2004. From August 1998 to November 2011, she served as a lecturer and associate professor at the School of Business Administration of Shenyang Pharmaceutical University. From December 2011 to September 2020, she was a professor and PhD supervisor. In October 2020, she joined the School of Pharmaceutical Sciences of Tsinghua University as a researcher and PhD supervisor. Currently, she is the leader of the discipline of drug regulatory science of Tsinghua University, the director of the Key Laboratory of Innovative Drug Research and Evaluation of National Medical Products Administration, and a director of China Center for International Economic Exchanges.

Mr. Zhang was appointed as an independent non-executive director on June 2020. Mr. Zhang, as a Chinese Certified Public Accountant and Senior Accountant, graduated in accounting from Jiangxi University of Finance and Economics, the PRC in July 1985, and graduated in law from Party School of the Central Committee of C.P.C in December 2001. Mr. Zhang previously worked at the Industry and Transport Division of the Department of Finance of Jiangsu Province, Jiangsu High and New Technology Venture Capital Company, Jiangsu Assets and Equity Exchang and Jiangsu Asset Appraisal Company. Also he served as the director of Jiangsu Certified Public Accountants Company, was the director of the asset appraisal center under the Department of Finance of Jiangsu Province and held the division chief of Jiangsu Rural Comprehensive Reform Working Group Office.

Mr. Xiong is the chairman of the board, executive director and the legal representative of our company. He is responsible for the overall management, implementing decisions and operations of the Company. Mr. Xiong obtained his bacherlor's degree in investment economics management from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) and MBA from the Chinese University of Hong Kong. Mr.Xiong has more than 20 years of experience in pharmaceutical investment and management of pharmaceutical enterprises. Mr. Xiong had perviously worked at Guolian Fund Management Co., Ltd., Shanghai Union Biopharm.Co., Ltd., and etc. Now Mr.Xiong acts as the chairman of the Company, and executive director, chairman and general manager of several subsidiaries of the Company, and executive director of Shanghai Baoying Asset Management Co., Ltd.

Dr.Zuo is responsible for formulating business strategies and managing operation of the Company. Dr. Zou joined the Group in April 2022 and was appointed to the Board in June 2022. Dr. Zou has over 20 years of experience in the healthcare sector. From August 1995 to September 2005, she served as the resident and attending physician at the department of oncology under the department of clinical medicine at the 301 Hospital of the People’s Liberation Army and at the department of oncology at the Shanghai Changzheng Hospital respectively. From October 2005 to October 2012, she served as the medical manager of the research and development department and the head of the oncology therapeutic team of Bayer China, and the head of global medical affairs at the United States headquarters of Bayer Pharmaceuticals in New Jersey. From October 2012 to September 2015, she served as the head of China Medical Affairs at Celgene Pharmaceuticals in the United States. From September 2015 to April 2022, she served as the chief medical officer and deputy general manager at Jiangsu Hengrui Pharmaceutical Co., Ltd. Dr. Zou graduated with a bachelor’s degree in clinical medicine from the Fourth Military Medical University in July 1995. She graduated with a doctorate degree in clinical oncology from the Second Military Medical University in August 2005.

Dr. Feng was appointed as an independent non-executive director from November 2021. Dr. Feng obtained his bachelor’s degree in medicine from Shanghai First Medical College (now known as Shanghai Medical College of Fudan University) in December 1982 and a doctor’s degree in diagnostic radiology in December 1988. He served as the deputy dean and secretary of the Party Committee at Huashan Hospital of Fudan University from April 2000 to May 2008. From May 2007 to June 2011, he served as the dean of Shanghai Medical College of Fudan University. He served as the vice president of Fudan University from May 2011 to July 2015 and since August 2016, he served as a tenured professor at Huashan Hospital of Fudan University. He has been appointed as the chairman of Lunqin (Shanghai) Medical Technology Co., Ltd since November 2016. He served as the dean of Shanghai Penta Innovation & Entrepreneurship Institute since January 2018. He also served as the president of Shanghai Society of Biotechnology since October 2018.

Dr. Yang was appointed as an independent non-executive director on June, 2024. Dr. Yang obtained her bachelor’s degree in pharmaceutical business management from Shenyang Pharmaceutical University in July 1995, obtained her master’s degree in pharmacology from Shenyang Pharmaceutical University in July 1998, and obtained her doctoral degree in pharmacy from Shenyang Pharmaceutical University in July 2004. From August 1998 to November 2011, she served as a lecturer and associate professor at the School of Business Administration of Shenyang Pharmaceutical University. From December 2011 to September 2020, she was a professor and PhD supervisor. In October 2020, she joined the School of Pharmaceutical Sciences of Tsinghua University as a researcher and PhD supervisor. Currently, she is the leader of the discipline of drug regulatory science of Tsinghua University, the director of the Key Laboratory of Innovative Drug Research and Evaluation of National Medical Products Administration, and a director of China Center for International Economic Exchanges.

Mr. Xiong is the chairman of the board, executive director and the legal representative of our company. He is responsible for the overall management, implementing decisions and operations of the Company. Mr. Xiong obtained his bacherlor's degree in investment economics management from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) and MBA from the Chinese University of Hong Kong. Mr.Xiong has more than 20 years of experience in pharmaceutical investment and management of pharmaceutical enterprises. Mr. Xiong had perviously worked at Guolian Fund Management Co., Ltd., Shanghai Union Biopharm.Co., Ltd., and etc. Now Mr.Xiong acts as the chairman of the Company, and executive director, chairman and general manager of several subsidiaries of the Company, and executive director of Shanghai Baoying Asset Management Co., Ltd.

Dr.Zuo is responsible for formulating business strategies and managing operation of the Company. Dr. Zou joined the Group in April 2022 and was appointed to the Board in June 2022. Dr. Zou has over 20 years of experience in the healthcare sector. From August 1995 to September 2005, she served as the resident and attending physician at the department of oncology under the department of clinical medicine at the 301 Hospital of the People’s Liberation Army and at the department of oncology at the Shanghai Changzheng Hospital respectively. From October 2005 to October 2012, she served as the medical manager of the research and development department and the head of the oncology therapeutic team of Bayer China, and the head of global medical affairs at the United States headquarters of Bayer Pharmaceuticals in New Jersey. From October 2012 to September 2015, she served as the head of China Medical Affairs at Celgene Pharmaceuticals in the United States. From September 2015 to April 2022, she served as the chief medical officer and deputy general manager at Jiangsu Hengrui Pharmaceutical Co., Ltd. Dr. Zou graduated with a bachelor’s degree in clinical medicine from the Fourth Military Medical University in July 1995. She graduated with a doctorate degree in clinical oncology from the Second Military Medical University in August 2005.

Dr. Meng was appointed as an independent non-executive director on June 2023. Dr. Meng received a bachelor’s degree in agronomy from
Southwest Agricultural University* (西南農業大學) in July 1983, and a doctorate degree in genetics from the University of Nottingham in November 1990. He was elected as an academician of the Chinese Academy of Sciences in 2007 and an academician of The World Academy of Sciences for the advancement of science in developing countries in 2008. From December 1990 to December 1992, he worked as a postdoctoral researcher at the School of Biology, China Agricultural University. From December 1992 to August 1998, he served as an associate professor at the School of Biology, China Agricultural University, during which from March 1996 to August 1998, he was a visiting scholar at the Institute of Molecular Medicine and Genetics, Medical College of Georgia in the United States. Since August 1998, he has been a professor at the School of Life Sciences, Tsinghua University.

Mr. Zhang was appointed as an independent non-executive director on June 2020. Mr. Zhang, as a Chinese Certified Public Accountant and Senior Accountant, graduated in accounting from Jiangxi University of Finance and Economics, the PRC in July 1985, and graduated in law from Party School of the Central Committee of C.P.C in December 2001. Mr. Zhang previously worked at the Industry and Transport Division of the Department of Finance of Jiangsu Province, Jiangsu High and New Technology Venture Capital Company, Jiangsu Assets and Equity Exchang and Jiangsu Asset Appraisal Company. Also he served as the director of Jiangsu Certified Public Accountants Company, was the director of the asset appraisal center under the Department of Finance of Jiangsu Province and held the division chief of Jiangsu Rural Comprehensive Reform Working Group Office.

Dr. Shen was appointed as an independent non-executive director on June, 2024. Dr. Shen obtained his bachelor’s degree in pharmacy from Shanghai First Medical College in August 1975, obtained his master of science in pharmacy from Shanghai Medical University in July 1986, obtained his doctoral degree in pharmacy from Kyoto University in Japan in September 1993, and engaged in postdoctoral research in pharmacy at Shanghai Institute of Materia Medica, Chinese Academy of Sciences from January 1994 to September 1995. From September 1995 to May 2016, he worked as a researcher and PhD supervisor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has served as the chairman of the board of directors of Shanghai Ringene Biopharma Co. Ltd. since September 2018 and an independent director of Yantai MabPlex International Biomedical Co., Ltd. since January 2022.